Important Class Action Notice for Shareholders of Capricor Therapeutics (CAPR)

Overview

On August 21, 2025, The Gross Law Firm issued a significant announcement directed at shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR), informing them of an impending class action lawsuit. Shareholders who acquired shares during the specified period are encouraged to act swiftly to protect their interests. The deadline to take necessary actions, including seeking appointment as lead plaintiff, is set for September 15, 2025.

What is the Class Action About?

The class action relates to allegations against Capricor Therapeutics and its misleading statements regarding their lead cell therapy candidate, deramiocel. This drug was designed to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The complaint indicates that the company may have provided investors with excessively optimistic claims about their ability to secure a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA).

Specifically, it claims that while portraying a positive image to shareholders, Capricor failed to disclose critical negative information, particularly concerning the safety and efficacy outcomes from their Phase 2 HOPE-2 trial regarding deramiocel.

On July 11, 2025, Capricor revealed that it received a Complete Response Letter (CRL) from the FDA, highlighting that their application did not meet the required standards and necessitated more clinical data. Following this press release, the stock price of Capricor plummeted from $11.40 on July 10 to approximately $7.64 by the next day, reflecting drastic investor reaction and loss.

Why You Should Participate

If you have purchased shares of CAPR between October 9, 2024, and July 10, 2025, it is crucial to act quickly. Registering will not only enroll you in the case but also provide you with updates through sophisticated portfolio monitoring software. Participation as a lead plaintiff is optional; however, your engagement is vital for potential recovery of losses incurred during the specified class period.

Next Steps for Shareholders

Interested shareholders should register here without delay to ensure their interests are represented in this class action. The form takes only a few moments to complete.

About The Gross Law Firm

The Gross Law Firm is well-regarded nationally and is dedicated to advocating for shareholders and investors who have been affected by unlawful business tactics or deceptive practices in the financial markets. Their commitment is to hold companies accountable for their actions which lead to such manipulative situations, ensuring they adhere to ethical corporate conduct. Participation in this case is free of charge and offers a pathway for recovery.

As a shareholder, empowering yourself by joining this class action can be a decisive step towards reclaiming your lost investments.